-
4-Phenylbutyric Acid for ER Stress Workflows
2026-09-11
Use 4-PBA as a mechanistic rescue tool, not merely an ER stress marker, to test whether stress signaling drives apoptosis or cytotoxic autophagy. This workflow translates liver cancer findings into practical dosing, controls, endpoint selection, and troubleshooting strategies.
-
Preserving Protein Signals in Atopic Dermatitis Research
2026-09-11
Translational atopic dermatitis research depends on more than an effective formulation: it also requires sample preparation that preserves the molecular evidence behind therapeutic decisions. This article connects melatonin-loaded sacchachitin nanofiber hydrogel research with a practical, EDTA-free strategy for protecting proteins during extraction, Western blotting, co-immunoprecipitation, and phosphorylation analysis.
-
Recombinant Mouse Sonic Hedgehog Workflow
2026-09-10
Use Recombinant Mouse Sonic Hedgehog to connect controlled dose-response assays with ex vivo developmental models. This workflow combines alkaline phosphatase benchmarking, genital-tubercle culture, cross-species comparisons, and practical troubleshooting for congenital malformation research.
-
nPEC for Dual-Loaded Liposome Encapsulation
2026-09-10
The reference study compares separation workflows for measuring encapsulation efficiency when liposomes contain hydrophilic and lipophilic drugs together. It identifies nanoparticle exclusion chromatography coupled with online HPLC as the most broadly applicable approach among the tested methods, including for oleanolic acid and doxorubicin hydrochloride co-loaded liposomes.
-
12-O-tetradecanoyl phorbol-13-acetate (TPA) Workflows
2026-09-09
Build time-resolved PKC and ERK/MAPK experiments with 12-O-tetradecanoyl phorbol-13-acetate (TPA), from biochemical kinase assays to neuronal injury and skin cancer models. This practical guide connects pathway activation with mitochondrial, autophagy, viability, and tumor-promotion readouts while emphasizing controls and troubleshooting.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Workflow
2026-09-09
Use dual Cy5 and EGFP signals to separate cellular uptake from productive translation in one reporter workflow. This guide shows how to apply the reagent to nanoparticle validation, macrophage delivery studies, quantitative transfection assays, and troubleshooting without confusing fluorescent cargo presence with functional gene expression.
-
KJG, TLR4, and Neuroinflammation in Depression
2026-09-08
The reference study combines network pharmacology with mouse and cell experiments to show that Kaixin Jieyu Granule may reduce depressive-like behavior by suppressing TLR4-associated neuroinflammation through the PI3K/AKT/FOXO1 axis. Its design also illustrates how TAK-242 and pathway-directed pharmacology can be used to test mechanistic links, while highlighting the limits of translating a multi-component herbal intervention into a single molecular explanation.
-
SP1/ADAM10/DRP1 Axis in Hypoxic Pulmonary Hypertension
2026-09-08
This 2025 study identifies an SP1/ADAM10/DRP1 signaling axis that connects hypoxia-stressed endothelial cells with pathological smooth muscle cell behavior in hypoxic pulmonary hypertension. Its conditioned-medium and inhibitor experiments position endothelial ADAM10 upstream of DRP1 and PI3K/AKT/mTOR signaling, providing a mechanistic framework for studying pulmonary vascular remodeling.
-
Direct Mouse Genotyping Kit: PCR Workflow
2026-09-07
The Direct Mouse Genotyping Kit supports rapid genomic DNA release and PCR amplification from mouse tissue without conventional DNA purification. It is suited to routine mouse genetic screening and high-throughput genotyping, but purified DNA should be prepared separately when downstream applications require stringent DNA quality or quantitative analysis.
-
Metabolomics of Carbapenemase-Producing Enterobacterales
2026-09-07
A 2025 study used LC-MS/MS metabolomics and machine learning to distinguish carbapenemase-producing Enterobacterales from non-CPE isolates without antibiotic exposure. Its metabolite biomarkers and pathway-level results support faster resistance detection while also highlighting metabolic processes that may contribute to the resistant phenotype.
-
MMP7-Driven EMT in Biliary Atresia Liver Fibrosis
2026-09-05
The reference study identifies MMP7 as a mechanistic driver of epithelial–mesenchymal transition and progressive liver fibrosis in biliary atresia. By connecting MMP7-mediated E-cadherin cleavage with β-catenin nuclear translocation, the work provides a testable framework for studying post-surgical fibrotic progression and targeted intervention.
-
PBS Liposomes for Macrophage Control Studies
2026-09-04
PBS Liposomes provide a phagocytosis-matched, non-cytotoxic comparator for separating liposome uptake from clodronate-driven macrophage depletion. This guide explains paired in vivo and cell-based workflows, practical controls, optimization strategies, and interpretation limits for reproducible immune research.
-
Adipocyte-Targeted CRISPRi for Obesity and Fatty Liver
2026-09-04
The reference study combines adipose-tissue targeting with CRISPR interference to silence Fabp4 selectively in mature white adipocytes. In obese mice, this strategy reduced adiposity and inflammation while improving hepatic steatosis and insulin resistance, illustrating how tissue-restricted gene regulation can address interconnected metabolic disease.
-
Cyclosporin A: From Mechanism to Assay Design
2026-09-03
Cyclosporin A is more than an immunosuppressant: it is a pathway-level probe linking cyclophilin biology, calcineurin-NFAT signaling, mitochondria, and apoptosis. This guide explains how delivery research on luteolin can sharpen exposure controls and assay interpretation without overstating cross-model evidence.
-
Optimizing hiPSC-Derived Platelet Production
2026-09-03
A 2026 study developed an optimized differentiation scheme that combines higher embryoid body input, human platelet lysate, and small-molecule control of megakaryocyte development. The resulting platform shortened production to 19 days, increased functional platelet yield, and reduced estimated costs, providing a practical framework for scalable hiPSC-derived platelet manufacturing.